Skip to content

Moxibustion and moxibustion with salt to Improve the Regulation of PGI, PGII, PGR and G-17 Clinical Randomized Controlled Study of Gastrointestinal Reaction after Chemotherapy for Breast Cancer

Moxibustion and moxibustion with salt to Improve the Regulation of PGI, PGII, PGR and G-17 Clinical Randomized Controlled Study of Gastrointestinal Reaction after Chemotherapy for Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021104
Enrollment
Unknown
Registered
2019-01-28
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Group 2:mild moxibustion
moxibustion with salt
Group 1:moxibustion with salt

Sponsors

Affiliated Hospital of Nanjing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria of the Breast Cancer Screening and Diagnosis(2017. V3), 2017 edition of the NCCN Clinical Practice Guide: (1) All cases of breast cancer diagnosed by pathological examination and patients requiring chemotherapy without distant transfer; (2) Excluding the contraindications of chemotherapy, the general situation of patients before chemotherapy and the absence of abnormalities in pepsin and gastrin; (3) Chemotherapy with cyclophosphamide, anthracycline and taxol are selected according to the guidelines. Inclusion of standards: (1) meet the diagnostic criteria; (2) Aged 18 to 70 years; (3) Informed and voluntary treatment.

Exclusion criteria

Exclusion criteria: (1) merger of persons with mental illness; (2) vomiting caused by abnormal pepsin, gastrin or other causes other than chemotherapy before chemotherapy; (3) Patients with a previous history of gastrointestinal diseases; (4) Pregnant or lactating women; (5) The subject is unwilling to participate in the trial or does not cooperate with the treatment.

Design outcomes

Primary

MeasureTime frame
PG I;PG II;PGR;G-17;nausea;vomit;astriction;diarrhea;

Countries

China

Contacts

Public ContactGUO Qi

Affiliated Hospital of Nanjing University of Traditional Chinese Medicine

gq0705@163.com+86 13838105462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026